testing / Shutterstock.com

15 February 2024Big PharmaMarisa Woutersen

MSD can appeal SPC ruling due to 'wrongly decided' case

Judge says UK courts should depart from a European precedent following Brexit | MSD counsel says appeal had been granted due to courts' “flip-flopping” on the precedent(s) set by the landmark cases Neurim and Santen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More on this story

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

More features

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals

Panitch Schwarze hires experienced ex-USPTO examiner

Fed Circ affirms generic’s litigation costs of $12m are tax-deductible

Genmab fights claim over 'secrets theft' behind $1.8bn takeover